KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $235000.0.

  • Aquestive Therapeutics' Capital Expenditures rose 19375.0% to $235000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $492000.0, marking a year-over-year increase of 20750.0%. This contributed to the annual value of $159000.0 for FY2024, which is 8402.01% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Capital Expenditures is $235000.0, which was up 19375.0% from $107000.0 recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Capital Expenditures peaked at $826000.0 during Q2 2023, and registered a low of $2000.0 during Q1 2023.
  • For the 5-year period, Aquestive Therapeutics' Capital Expenditures averaged around $187789.5, with its median value being $104000.0 (2022).
  • As far as peak fluctuations go, Aquestive Therapeutics' Capital Expenditures plummeted by 9807.69% in 2023, and later surged by 135000.0% in 2024.
  • Aquestive Therapeutics' Capital Expenditures (Quarter) stood at $533000.0 in 2021, then crashed by 95.12% to $26000.0 in 2022, then crashed by 38.46% to $16000.0 in 2023, then dropped by 6.25% to $15000.0 in 2024, then soared by 1466.67% to $235000.0 in 2025.
  • Its Capital Expenditures stands at $235000.0 for Q3 2025, versus $107000.0 for Q2 2025 and $135000.0 for Q1 2025.